See the DrugPatentWatch profile for zilbrysq
The market for zilucoplan, marketed as Zilbrysq, is focused on the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive [1]. Zilbrysq is a targeted therapy that inhibits the complement cascade [2].
What is generalized myasthenia gravis (gMG)?
Generalized myasthenia gravis is a rare, chronic autoimmune neuromuscular disease. In gMG, the immune system mistakenly attacks communication pathways between nerves and muscles, leading to debilitating muscle weakness that can affect any voluntary muscle in the body [1][3]. Patients often experience fatigue, difficulty speaking, swallowing, chewing, and breathing [3].
How does Zilbrysq work?
Zilbrysq works by inhibiting the complement cascade, specifically targeting the C5 protein. The complement system is part of the immune system that, in gMG, can mistakenly attack the neuromuscular junction. By blocking C5, Zilbrysq prevents the formation of the membrane attack complex, thereby reducing the damage to the neuromuscular junction and improving muscle strength [2].
When did Zilbrysq receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Zilbrysq for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive on October 25, 2023 [1].
What is the recommended dosage for Zilbrysq?
The recommended dosage for Zilbrysq is 45 mg administered subcutaneously once daily [1].
What are the potential side effects of Zilbrysq?
Common side effects reported with Zilbrysq include [1]:
* Infusion-related reactions
* Meningitis
* Nausea
* Diarrhea
* Muscle spasms
* Headache
* Complement mediated reactions
Zilbrysq carries a boxed warning for the risk of meningococcal infections [1]. Patients should be vaccinated against Neisseria meningitidis serogroups A, B, C, W, and Y before starting treatment and should remain up to date with vaccinations during treatment [1].
How does Zilbrysq compare to other gMG treatments?
Zilbrysq is a targeted therapy within the broader gMG treatment landscape, which includes immunosuppressants, plasma exchange, intravenous immunoglobulin (IVIg), and other complement inhibitors [3]. Unlike broad immunosuppressants, Zilbrysq targets a specific part of the immune cascade, aiming for a more precise approach [2].
Who manufactures Zilbrysq?
Zilbrysq is manufactured by Alexion Pharmaceuticals, a subsidiary of AstraZeneca [1].
What is the patent status of Zilucoplan?
Information regarding the specific patent expiry dates for zilucoplan (Zilbrysq) can be found on resources like DrugPatentWatch.com [4]. This information is crucial for understanding potential market entry timelines for generic or biosimilar versions of the drug.
Are there any contraindications for Zilbrysq?
Zilbrysq is contraindicated in patients with active Neisseria meningitidis infection or who are unvaccinated against Neisseria meningitidis [1].
What clinical trials support Zilbrysq's efficacy?
The FDA approval of Zilbrysq was based on data from the open-label Phase 3 trial, ENVISION, and its open-label extension study, which demonstrated sustained improvements in gMG symptoms and patient-reported outcomes [1].
What patient support is available for Zilbrysq?
Information on patient support programs for Zilbrysq may be available through the manufacturer. These programs often help with treatment access, financial assistance, and educational resources [1].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/zilbrysq-zilucoplan
[2] https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-announces-fda-approval-of- Zilbrysq-zilucoplan-for-adults-with-generalized-myasthenia-gravis.html
[3] https://www.myasthenia.org/What-is-MG/MG-Overview
[4] https://www.drugpatentwatch.com/